$INVA
Innoviva, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024023237 Filed on February 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $77.50M $85.84M $310.5M
YoY Change 1.48% 30.45% -6.3%
Cost Of Revenue $10.97M $13.13M $42.64M
YoY Change 6.01% 29.83% 209.14%
Gross Profit $66.53M $72.71M $267.8M
YoY Change 0.76% 30.56% -15.66%
Gross Profit Margin 85.84% 84.7% 86.27%
Selling, General & Admin $30.41M $26.32M $98.23M
YoY Change 54.07% 50.79% 54.6%
% of Gross Profit 45.7% 36.2% 36.68%
Research & Development $3.878M $2.356M $33.92M
YoY Change -69.19% -76.4% -18.13%
% of Gross Profit 5.83% 3.24% 12.67%
Depreciation & Amortization $9.950M $10.00M $35.71M
YoY Change 36.6% 42.83% 82.99%
% of Gross Profit 14.96% 13.76% 13.33%
Operating Expenses $34.28M $35.18M $132.2M
YoY Change 6.06% 11.67% 25.9%
Operating Profit $32.25M $37.53M $135.7M
YoY Change -4.32% 55.18% -36.18%
Interest Expense $5.851M $24.36M $19.16M
YoY Change 32.17% -128.24% 21.33%
% of Operating Profit 18.15% 64.91% 14.12%
Other Income/Expense, Net -$1.236M -$680.0K -$4.969M
YoY Change -8.17% -74.08% 47.32%
Pretax Income $45.12M $61.20M $194.1M
YoY Change 9.68% -194.61% -32.36%
Income Tax $8.600M -$330.0K $14.38M
% Of Pretax Income 19.06% -0.54% 7.41%
Net Earnings $36.53M $61.53M $179.7M
YoY Change 4.78% -190.07% -18.41%
Net Earnings / Revenue 47.14% 71.68% 57.89%
Basic Earnings Per Share $0.58 $2.75
Diluted Earnings Per Share $0.46 $0.72 $2.20
COMMON SHARES
Basic Shares Outstanding 63.23M 64.09M 65.44M
Diluted Shares Outstanding 84.53M 86.88M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $178.4M $193.5M $193.5M
YoY Change 23.82% -33.51% -33.51%
Cash & Equivalents $178.4M $193.5M $193.5M
Short-Term Investments
Other Short-Term Assets $2.987M $4.264M $25.89M
YoY Change 5.88% 45.38% -20.31%
Inventory $37.44M $40.74M $40.74M
Prepaid Expenses
Receivables $76.01M $84.08M $84.08M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $311.3M $344.2M $344.2M
YoY Change 5.02% -22.39% -22.39%
LONG-TERM ASSETS
Property, Plant & Equipment $324.0K $483.0K $3.019M
YoY Change 80.0% 184.12% -12.11%
Goodwill $17.90M $17.90M
YoY Change -35.84% -32.96%
Intangibles $223.9M $230.3M
YoY Change -9.83% -8.93%
Long-Term Investments $628.4M $561.0M $561.0M
YoY Change 37.86% 39.2% 39.2%
Other Assets $3.112M $3.267M $3.267M
YoY Change -20.06% -24.01% -24.01%
Total Long-Term Assets $956.3M $899.3M $899.3M
YoY Change 14.75% 14.12% 14.12%
TOTAL ASSETS
Total Short-Term Assets $311.3M $344.2M $344.2M
Total Long-Term Assets $956.3M $899.3M $899.3M
Total Assets $1.268B $1.244B $1.244B
YoY Change 12.2% 0.98% 0.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $890.0K $6.717M $6.717M
YoY Change -85.0% 128.55% 128.55%
Accrued Expenses $20.35M $30.14M $30.14M
YoY Change -32.08% -10.27% -10.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $29.88M $38.13M $38.13M
YoY Change -21.65% -71.75% -71.75%
LONG-TERM LIABILITIES
Long-Term Debt $446.8M $446.2M $446.2M
YoY Change 0.46% 0.46% 0.46%
Other Long-Term Liabilities $71.69M $71.87M $83.62M
YoY Change 2.21% 1.34% 3.5%
Total Long-Term Liabilities $518.4M $518.1M $529.9M
YoY Change 0.7% 0.58% 0.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.88M $38.13M $38.13M
Total Long-Term Liabilities $518.4M $518.1M $529.9M
Total Liabilities $548.3M $556.2M $568.6M
YoY Change -0.84% -14.43% -14.59%
SHAREHOLDERS EQUITY
Retained Earnings $11.34M -$25.19M
YoY Change -106.67% -87.71%
Common Stock $1.086B $1.094B
YoY Change -3.48% -6.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $703.7M $675.0M $675.0M
YoY Change
Total Liabilities & Shareholders Equity $1.268B $1.244B $1.244B
YoY Change 12.2% 0.98% 0.98%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income $36.53M $61.53M $179.7M
YoY Change 4.78% -190.07% -18.41%
Depreciation, Depletion And Amortization $9.950M $10.00M $35.71M
YoY Change 36.6% 42.83% 82.99%
Cash From Operating Activities $37.05M $33.26M $141.1M
YoY Change 44.24% 273.79% -30.07%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $111.0K $411.0K
YoY Change -100.0% 226.47% 513.43%
Acquisitions
YoY Change
Other Investing Activities -$43.04M -$4.950M -$66.35M
YoY Change 20.59% -42.73% 17.29%
Cash From Investing Activities -$43.04M -$5.161M -$66.76M
YoY Change 20.48% -40.53% 17.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $75.56M
YoY Change 829.03%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -9.165M -14.54M -171.8M
YoY Change -93.31% 45.38% 209.24%
NET CHANGE
Cash From Operating Activities 37.05M 33.26M 141.1M
Cash From Investing Activities -43.04M -5.161M -66.76M
Cash From Financing Activities -9.165M -14.54M -171.8M
Net Change In Cash -15.16M 13.56M -97.54M
YoY Change -89.69% -238.69% -208.95%
FREE CASH FLOW
Cash From Operating Activities $37.05M $33.26M $141.1M
Capital Expenditures $0.00 $111.0K $411.0K
Free Cash Flow $37.05M $33.15M $140.7M
YoY Change 44.43% 273.98% -30.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001080014
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LiabilitiesAndStockholdersEquity
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
000-30319
CY2023 dei Entity Registrant Name
EntityRegistrantName
INNOVIVA, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3265960
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1350 Old Bayshore Highway, Suite 400
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Burlingame
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94010
CY2023 dei City Area Code
CityAreaCode
650
CY2023 dei Local Phone Number
LocalPhoneNumber
238-9600
CY2023 dei Security12b Title
Security12bTitle
Common Stock $0.01 Par Value
CY2023 dei Trading Symbol
TradingSymbol
INVA
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
false
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
731926690000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
63227333
CY2023 dei Auditor Firm
AuditorFirmId
34
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
193513000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
291049000
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
14454000
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
9401000
CY2023Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
69621000
CY2022Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
54672000
CY2023Q4 us-gaap Inventory Net
InventoryNet
40737000
CY2022Q4 us-gaap Inventory Net
InventoryNet
55897000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21630000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
29559000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4264000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2933000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
344219000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
443511000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
483000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
170000
CY2023Q4 inva Equity Method Investment
EquityMethodInvestment
116546000
CY2022Q4 inva Equity Method Investment
EquityMethodInvestment
39154000
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
444432000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
363859000
CY2023Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
83784000
CY2022Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
97607000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2536000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3265000
CY2023Q4 us-gaap Goodwill
Goodwill
17905000
CY2022Q4 us-gaap Goodwill
Goodwill
26713000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
230335000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
252919000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3267000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4299000
CY2023Q4 us-gaap Assets
Assets
1243507000
CY2022Q4 us-gaap Assets
Assets
1231497000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6717000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2939000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7020000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8022000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3422000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4359000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1277000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2094000
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0
CY2022Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
96193000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
154000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
19698000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21207000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38134000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
134968000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
446234000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
444180000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
71870000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
70918000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
563000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
5771000
CY2023Q4 inva Income Tax Payable Non Current
IncomeTaxPayableNonCurrent
11751000
CY2022Q4 inva Income Tax Payable Non Current
IncomeTaxPayableNonCurrent
9872000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63307000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63307000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69188000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69188000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
633000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
692000
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
32005000
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
32005000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
393829000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
393829000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1093340000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1163836000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25189000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-204911000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
674955000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
565788000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1243507000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1231497000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
310463000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
331339000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
391866000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
98232000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
63538000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16187000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33922000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41432000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
576000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
21784000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5581000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2023 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
0
CY2022 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
266696000
CY2021 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
0
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-20662000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
77392000
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-161749000
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
84392000
CY2023 inva Gain Loss On Other Investments
GainLossOnOtherInvestments
11129000
CY2022 inva Gain Loss On Other Investments
GainLossOnOtherInvestments
8462000
CY2021 inva Gain Loss On Other Investments
GainLossOnOtherInvestments
6638000
CY2023 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
15818000
CY2022 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
6369000
CY2021 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
1839000
CY2023 us-gaap Interest Expense
InterestExpense
19157000
CY2022 us-gaap Interest Expense
InterestExpense
15789000
CY2021 us-gaap Interest Expense
InterestExpense
19070000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4969000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3373000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3626000
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
116365000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
44390000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
-53410000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
194098000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
286949000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
445276000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14376000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
66687000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
76439000
CY2023 us-gaap Profit Loss
ProfitLoss
179722000
CY2022 us-gaap Profit Loss
ProfitLoss
220262000
CY2021 us-gaap Profit Loss
ProfitLoss
368837000
CY2023 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
6341000
CY2021 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
102983000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
179722000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
213921000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
265854000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.75
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.07
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.24
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.2
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.37
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.87
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65435000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69644000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82062000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86876000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95248000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94310000
CY2023 us-gaap Profit Loss
ProfitLoss
179722000
CY2022 us-gaap Profit Loss
ProfitLoss
220262000
CY2021 us-gaap Profit Loss
ProfitLoss
368837000
CY2023 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
179722000
CY2022 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
220262000
CY2021 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
368837000
CY2023 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0
CY2022 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
6341000
CY2021 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
102983000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
179722000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
213921000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
265854000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
607837000
CY2021 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
59457000
CY2021 inva Changes To Noncontrolling Interest From A Consolidated Variable Interest Entity
ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
-259000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1109000
CY2021 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
394149000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2017000
CY2021 us-gaap Profit Loss
ProfitLoss
368837000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
525935000
CY2022 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
69811000
CY2022 inva Recognition Of Noncontrolling Interest Upon Initial Consolidation Of Entasis
RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis
38471000
CY2022 inva Changes To Noncontrolling Interest From A Consolidated Variable Interest Entity
ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
-2000
CY2022 inva Derecognition Of Noncontrolling Interests Upon Sale Of Trc
DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
-61226000
CY2022 inva Derecognition Of Non Controlling Interests Upon Acquisition Of Entasis Minority Interest
DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
-42162000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
288000
CY2022 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
-16585000
CY2022 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
3000
CY2022 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
8503000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7347000
CY2022 us-gaap Profit Loss
ProfitLoss
220262000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
565788000
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
92000
CY2023 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
76484000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5837000
CY2023 us-gaap Profit Loss
ProfitLoss
179722000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
674955000
CY2023 us-gaap Profit Loss
ProfitLoss
179722000
CY2022 us-gaap Profit Loss
ProfitLoss
220262000
CY2021 us-gaap Profit Loss
ProfitLoss
368837000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
4400000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
25006000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
76432000
CY2023 inva Amortization Of Capitalized Fees And Depreciation Of Property And Equipment
AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment
13921000
CY2022 inva Amortization Of Capitalized Fees And Depreciation Of Property And Equipment
AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment
13931000
CY2021 inva Amortization Of Capitalized Fees And Depreciation Of Property And Equipment
AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment
13832000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
21784000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5581000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2023 inva Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales
InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales
27164000
CY2022 inva Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales
InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales
10023000
CY2021 inva Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales
InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales
0
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
5837000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
7347000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2017000
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2065000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2055000
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
9136000
CY2023 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
77392000
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-161749000
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
84392000
CY2023 inva Unrealized Other Gain Loss On Investments
UnrealizedOtherGainLossOnInvestments
11129000
CY2022 inva Unrealized Other Gain Loss On Investments
UnrealizedOtherGainLossOnInvestments
8462000
CY2021 inva Unrealized Other Gain Loss On Investments
UnrealizedOtherGainLossOnInvestments
4917000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-20662000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
0
CY2022 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
266696000
CY2021 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
0
CY2023 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
517000
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3402000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
259000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5053000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3525000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2023 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
14949000
CY2022 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-13319000
CY2021 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
16780000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
12004000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-280000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-7929000
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
21350000
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-203000
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2965000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3341000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3778000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
92000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-39000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1498000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
11913000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-257000
CY2023 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-937000
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
207000
CY2021 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-817000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-755000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2023 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1725000
CY2022 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
10026000
CY2021 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
141064000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
201726000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
363813000
CY2023 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
0
CY2022 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
45000000
CY2021 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
44000000
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
65132000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
15905000
CY2023 us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
1218000
CY2022 us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
13725000
CY2021 us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
6373000
CY2023 inva Purchases Of Equity Investments Managed By Isp Fund Lp
PurchasesOfEquityInvestmentsManagedByIspFundLp
31164000
CY2022 inva Purchases Of Equity Investments Managed By Isp Fund Lp
PurchasesOfEquityInvestmentsManagedByIspFundLp
60910000
CY2021 inva Purchases Of Equity Investments Managed By Isp Fund Lp
PurchasesOfEquityInvestmentsManagedByIspFundLp
190970000
CY2023 inva Purchases Of Trading Security Managed By Isp Fund Lp
PurchasesOfTradingSecurityManagedByIspFundLp
0
CY2022 inva Purchases Of Trading Security Managed By Isp Fund Lp
PurchasesOfTradingSecurityManagedByIspFundLp
50000000
CY2021 inva Purchases Of Trading Security Managed By Isp Fund Lp
PurchasesOfTradingSecurityManagedByIspFundLp
0
CY2023 inva Sale Of Equity Investments Managed By Isp Fund Lp
SaleOfEquityInvestmentsManagedByIspFundLp
72500000
CY2022 inva Sale Of Equity Investments Managed By Isp Fund Lp
SaleOfEquityInvestmentsManagedByIspFundLp
24281000
CY2021 inva Sale Of Equity Investments Managed By Isp Fund Lp
SaleOfEquityInvestmentsManagedByIspFundLp
21440000
CY2023 inva Purchase And Sale Of Other Investments Managed By Isp Fund Lp
PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
41336000
CY2022 inva Purchase And Sale Of Other Investments Managed By Isp Fund Lp
PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
23371000
CY2021 inva Purchase And Sale Of Other Investments Managed By Isp Fund Lp
PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
-279530000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
411000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2023 inva Net Proceeds From Sale Of Variable Interest Entity Equity
NetProceedsFromSaleOfVariableInterestEntityEquity
0
CY2022 inva Net Proceeds From Sale Of Variable Interest Entity Equity
NetProceedsFromSaleOfVariableInterestEntityEquity
248191000
CY2021 inva Net Proceeds From Sale Of Variable Interest Entity Equity
NetProceedsFromSaleOfVariableInterestEntityEquity
0
CY2023 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2022 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
23070000
CY2021 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2023 inva Cash Paid For The Acquisition Of La Jolla Pharmaceutical Company Net Of Cash Acquired
CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired
0
CY2022 inva Cash Paid For The Acquisition Of La Jolla Pharmaceutical Company Net Of Cash Acquired
CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired
159103000
CY2021 inva Cash Paid For The Acquisition Of La Jolla Pharmaceutical Company Net Of Cash Acquired
CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired
0
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66761000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56634000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43722000
CY2023 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
0
CY2022 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
69811000
CY2021 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
59457000
CY2023 inva Purchase Of Entasis Noncontrolling Interest
PurchaseOfEntasisNoncontrollingInterest
0
CY2022 inva Purchase Of Entasis Noncontrolling Interest
PurchaseOfEntasisNoncontrollingInterest
43910000
CY2021 inva Purchase Of Entasis Noncontrolling Interest
PurchaseOfEntasisNoncontrollingInterest
0
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
75728000
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
8503000
CY2021 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
394149000
CY2023 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
77000
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
82000
CY2021 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
60000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
170000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
370000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1169000
CY2023 us-gaap Repayments Of Unsecured Debt
RepaymentsOfUnsecuredDebt
96204000
CY2022 us-gaap Repayments Of Unsecured Debt
RepaymentsOfUnsecuredDebt
165131000
CY2021 us-gaap Repayments Of Unsecured Debt
RepaymentsOfUnsecuredDebt
0
CY2023 inva Purchases Of Capped Call Options Associated With Convertible Senior Notes
PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes
0
CY2022 inva Purchases Of Capped Call Options Associated With Convertible Senior Notes
PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes
21037000
CY2021 inva Purchases Of Capped Call Options Associated With Convertible Senior Notes
PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes
0
CY2023 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2022 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
252536000
CY2021 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-171839000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-55568000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-452497000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-97536000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
89524000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-44962000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
291049000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201525000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
246487000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
193513000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
291049000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201525000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
11381000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
11736000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
9933000
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
53855000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023 inva Accrued Interest Income Included In Long Term Investments
AccruedInterestIncomeIncludedInLongTermInvestments
2666000
CY2022 inva Accrued Interest Income Included In Long Term Investments
AccruedInterestIncomeIncludedInLongTermInvestments
0
CY2021 inva Accrued Interest Income Included In Long Term Investments
AccruedInterestIncomeIncludedInLongTermInvestments
0
CY2023 inva Non Cash Activity
NonCashActivity
0
CY2022 inva Non Cash Activity
NonCashActivity
-28228000
CY2021 inva Non Cash Activity
NonCashActivity
0
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Management’s Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers and Partners</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (“API”) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK’s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Our royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts’ or investors’ expectations, due to a number of important factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We started recognizing revenue from product sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2022 as a result of our acquisition of La Jolla. In the current year, we also started recognizing revenue from product sales from XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which was commercially launched in the third quarter of 2023. Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">Three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of our customers each account for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our net product sales for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. These same customers account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in “Accounts receivables, net” in our consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Three of our customers each account for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our net product sales from the time of our acquisition of La Jolla through December 31, 2022. These same customers account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in “Accounts receivables, net” in our consolidated balance sheet as of December 31, 2022.</span></p>
CY2023 inva Number Of Customers
NumberOfCustomers
3
CY2023Q4 inva Capitalized Fee Paid Estimated Useful Life
CapitalizedFeePaidEstimatedUsefulLife
P15Y
CY2023 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
191304000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
225569000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
179722000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
213921000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
265854000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
270590000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65435000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69644000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82062000
CY2023 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
149000
CY2022 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
108000
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
59000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86876000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95248000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94310000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.75
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.07
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.24
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.2
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.37
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.87
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1924000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
930000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
979000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
170706000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
170706000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
263469000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
263469000
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 inva Convertible Senior Debt Fair Value Disclosures
ConvertibleSeniorDebtFairValueDisclosures
0
CY2023Q4 us-gaap Capitalized Contract Cost Gross
CapitalizedContractCostGross
220000000
CY2022Q4 us-gaap Capitalized Contract Cost Gross
CapitalizedContractCostGross
220000000
CY2023Q4 us-gaap Capitalized Contract Cost Accumulated Amortization
CapitalizedContractCostAccumulatedAmortization
136216000
CY2022Q4 us-gaap Capitalized Contract Cost Accumulated Amortization
CapitalizedContractCostAccumulatedAmortization
122393000
CY2023Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
83784000
CY2022Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
97607000
CY2023 inva Capitalized Fees Paid Weighted Average Useful Life
CapitalizedFeesPaidWeightedAverageUsefulLife
P6Y2M12D
CY2023Q4 inva Capitalized Fees Paid Remaining Estimated Amortization Next Twelve Months
CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths
13800000
CY2023Q4 inva Capitalized Fees Paid Remaining Estimated Amortization Year Two
CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo
13800000
CY2023Q4 inva Capitalized Fees Paid Remaining Estimated Amortization Yearthree
CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree
13800000
CY2023Q4 inva Capitalized Fees Paid Remaining Estimated Amortization Year Four
CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour
13800000
CY2023Q4 inva Capitalized Fees Paid Remaining Estimated Amortization Year Five
CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive
13700000
CY2023Q4 inva Capitalized Fees Paid Remaining Estimated Amortization After Year Five
CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive
14800000
CY2023Q4 us-gaap Goodwill
Goodwill
17900000
CY2022Q4 us-gaap Goodwill
Goodwill
26700000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q4 inva Intangible Assets Marketed Products Gross
IntangibleAssetsMarketedProductsGross
219700000
CY2023Q4 inva Intangible Assets Marketed Products Accumulated Amortization
IntangibleAssetsMarketedProductsAccumulatedAmortization
-25204000
CY2023Q4 inva Intangible Assets Marketed Products Net
IntangibleAssetsMarketedProductsNet
194496000
CY2023Q4 inva Intangible Assets In Process Research And Development Gross
IntangibleAssetsInProcessResearchAndDevelopmentGross
2600000
CY2023Q4 inva Intangible Assets In Process Research And Development Accumulated Amortization
IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization
0
CY2023Q4 inva Intangible Assets In Process Research And Development Net
IntangibleAssetsInProcessResearchAndDevelopmentNet
2600000
CY2023Q4 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2023Q4 inva Intangible Assets Collaboration Agreement Gross
IntangibleAssetsCollaborationAgreementGross
35400000
CY2023Q4 inva Intangible Assets Collaboration Agreement Accumulated Amortization
IntangibleAssetsCollaborationAgreementAccumulatedAmortization
-2161000
CY2023Q4 inva Intangible Assets Collaboration Agreement Net
IntangibleAssetsCollaborationAgreementNet
33239000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
257700000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-27365000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
230335000
CY2022Q4 inva Intangible Assets Marketed Products Gross
IntangibleAssetsMarketedProductsGross
151000000
CY2022Q4 inva Intangible Assets Marketed Products Accumulated Amortization
IntangibleAssetsMarketedProductsAccumulatedAmortization
-5581000
CY2022Q4 inva Intangible Assets Marketed Products Net
IntangibleAssetsMarketedProductsNet
145419000
CY2022Q4 inva Intangible Assets In Process Research And Development Gross
IntangibleAssetsInProcessResearchAndDevelopmentGross
72100000
CY2022Q4 inva Intangible Assets In Process Research And Development Accumulated Amortization
IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization
0
CY2022Q4 inva Intangible Assets In Process Research And Development Net
IntangibleAssetsInProcessResearchAndDevelopmentNet
72100000
CY2022Q4 inva Intangible Assets Collaboration Agreement Gross
IntangibleAssetsCollaborationAgreementGross
35400000
CY2022Q4 inva Intangible Assets Collaboration Agreement Accumulated Amortization
IntangibleAssetsCollaborationAgreementAccumulatedAmortization
0
CY2022Q4 inva Intangible Assets Collaboration Agreement Net
IntangibleAssetsCollaborationAgreementNet
35400000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
258500000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-5581000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
252919000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
11257000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5757000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
15670000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
25052000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
13810000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
25088000
CY2023Q4 us-gaap Inventory Net
InventoryNet
40737000
CY2022Q4 us-gaap Inventory Net
InventoryNet
55897000
CY2023Q4 inva Accrued Contract Manufacturing Liability
AccruedContractManufacturingLiability
1966000
CY2022Q4 inva Accrued Contract Manufacturing Liability
AccruedContractManufacturingLiability
8382000
CY2023Q4 inva Accrued Clinical Liability
AccruedClinicalLiability
591000
CY2022Q4 inva Accrued Clinical Liability
AccruedClinicalLiability
692000
CY2023Q4 inva Accrued Research Liability
AccruedResearchLiability
185000
CY2022Q4 inva Accrued Research Liability
AccruedResearchLiability
349000
CY2023Q4 inva Accrued Professional Services
AccruedProfessionalServices
8876000
CY2022Q4 inva Accrued Professional Services
AccruedProfessionalServices
3977000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1207000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1316000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1928000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0
CY2023Q4 inva Deferred Royalty Obligation Current
DeferredRoyaltyObligationCurrent
0
CY2022Q4 inva Deferred Royalty Obligation Current
DeferredRoyaltyObligationCurrent
2639000
CY2023Q4 inva Accrued License Fees And Royalties
AccruedLicenseFeesAndRoyalties
1575000
CY2022Q4 inva Accrued License Fees And Royalties
AccruedLicenseFeesAndRoyalties
943000
CY2023Q4 us-gaap Other Liabilities
OtherLiabilities
3370000
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
2909000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
19698000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
21207000
CY2023Q4 inva Deferred Royalty Obligation Non Current
DeferredRoyaltyObligationNonCurrent
69876000
CY2022Q4 inva Deferred Royalty Obligation Non Current
DeferredRoyaltyObligationNonCurrent
67947000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1635000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2376000
CY2023Q4 inva Contingent Value Rights Liability
ContingentValueRightsLiability
359000
CY2022Q4 inva Contingent Value Rights Liability
ContingentValueRightsLiability
595000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
71870000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
70918000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5837000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7347000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2017000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5837000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7347000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2017000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9511000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
453500000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
549704000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
7266000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
9331000
CY2023Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
446234000
CY2022Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
540373000
CY2023Q4 us-gaap Debt Current
DebtCurrent
0
CY2022Q4 us-gaap Debt Current
DebtCurrent
96193000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
446234000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
444180000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
192500000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
0
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
261000000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
453500000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
1428000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1585000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
189000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
155000
CY2023 us-gaap Lease Cost
LeaseCost
1617000
CY2022 us-gaap Lease Cost
LeaseCost
1740000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
1542000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
790000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3323000
CY2023 inva Right Of Use Assets Obtained Through Acquistions
RightOfUseAssetsObtainedThroughAcquistions
0
CY2022 inva Right Of Use Assets Obtained Through Acquistions
RightOfUseAssetsObtainedThroughAcquistions
1185000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2023 inva Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.076
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1373000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1428000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
143000
CY2023Q4 inva Lessee Operating Lease Liability To Be Paid After Year Three
LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
149000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3093000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
251000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2842000
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
7799000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
40822000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2177000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
464000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
7000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
9976000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
41286000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
7000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
6594000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
26026000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
70893000
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2194000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-625000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
5539000
CY2023 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
4400000
CY2022 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
25401000
CY2021 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
76432000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14376000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
66687000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
76439000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
40747000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
58928000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
93507000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1433000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1414000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
848000
CY2023 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-1582000
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-2453000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1260000
CY2023 us-gaap Income Tax Reconciliation Deductions Other
IncomeTaxReconciliationDeductionsOther
15274000
CY2022 us-gaap Income Tax Reconciliation Deductions Other
IncomeTaxReconciliationDeductionsOther
0
CY2021 us-gaap Income Tax Reconciliation Deductions Other
IncomeTaxReconciliationDeductionsOther
0
CY2023 us-gaap Income Tax Reconciliation Minority Interest Income Expense
IncomeTaxReconciliationMinorityInterestIncomeExpense
0
CY2022 us-gaap Income Tax Reconciliation Minority Interest Income Expense
IncomeTaxReconciliationMinorityInterestIncomeExpense
-7468000
CY2021 us-gaap Income Tax Reconciliation Minority Interest Income Expense
IncomeTaxReconciliationMinorityInterestIncomeExpense
21626000
CY2023 us-gaap Income Tax Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
0
CY2022 us-gaap Income Tax Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
-8897000
CY2021 us-gaap Income Tax Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
0
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1219000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-125000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1129000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-12167000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13180000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1321000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14376000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
66687000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
76439000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
182013000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
149646000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
21357000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
21230000
CY2023Q4 inva Deferred Tax Assets Unrealized Losses On Investment Net
DeferredTaxAssetsUnrealizedLossesOnInvestmentNet
0
CY2022Q4 inva Deferred Tax Assets Unrealized Losses On Investment Net
DeferredTaxAssetsUnrealizedLossesOnInvestmentNet
6032000
CY2023Q4 inva Deferred Tax Assets Deferred Royalty Obligation Net
DeferredTaxAssetsDeferredRoyaltyObligationNet
18084000
CY2022Q4 inva Deferred Tax Assets Deferred Royalty Obligation Net
DeferredTaxAssetsDeferredRoyaltyObligationNet
17404000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
6467000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
8527000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
227921000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
202839000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
169249000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
144808000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
58672000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
58031000
CY2023Q4 inva Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
-39064000
CY2022Q4 inva Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
-50587000
CY2023Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
13747000
CY2022Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
0
CY2023Q4 inva Deferred Tax Liabilities Inventory Fair Value Adjustment
DeferredTaxLiabilitiesInventoryFairValueAdjustment
-6424000
CY2022Q4 inva Deferred Tax Liabilities Inventory Fair Value Adjustment
DeferredTaxLiabilitiesInventoryFairValueAdjustment
-12410000
CY2023Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
0
CY2022Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
-805000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
563000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
5771000
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15185000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
313000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
14872000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1452000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
16324000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
3119000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
19443000
CY2023 dei Auditor Name
AuditorName
Deloitte & Touche LLP
CY2023 dei Auditor Location
AuditorLocation
San Jose, California
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 inva Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2023Q4 inva Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-023237-index-headers.html Edgar Link pending
0000950170-24-023237-index.html Edgar Link pending
0000950170-24-023237.txt Edgar Link pending
0000950170-24-023237-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img11953243_0.jpg Edgar Link pending
img11953243_1.jpg Edgar Link pending
img11953243_10.jpg Edgar Link pending
img11953243_11.jpg Edgar Link pending
img11953243_12.jpg Edgar Link pending
img11953243_13.jpg Edgar Link pending
img11953243_14.jpg Edgar Link pending
img11953243_15.jpg Edgar Link pending
img11953243_16.jpg Edgar Link pending
img11953243_17.jpg Edgar Link pending
img11953243_18.jpg Edgar Link pending
img11953243_19.jpg Edgar Link pending
img11953243_2.jpg Edgar Link pending
img11953243_20.jpg Edgar Link pending
img11953243_3.jpg Edgar Link pending
img11953243_4.jpg Edgar Link pending
img11953243_5.jpg Edgar Link pending
img11953243_6.jpg Edgar Link pending
img11953243_7.jpg Edgar Link pending
img11953243_8.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
img11953243_9.jpg Edgar Link pending
inva-20231231.htm Edgar Link pending
inva-20231231.xsd Edgar Link pending
inva-ex21_1.htm Edgar Link pending
inva-ex23_1.htm Edgar Link pending
inva-ex23_2.htm Edgar Link pending
inva-ex31_1.htm Edgar Link pending
inva-ex31_2.htm Edgar Link pending
inva-ex32.htm Edgar Link pending
inva-ex97.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
inva-20231231_htm.xml Edgar Link completed